Deep brain stimulation for parkinsonian gait disorders

Area of Science:

• Neurology
• Neurosurgery
• Movement Disorders

Background:

• Parkinson's disease (PD) motor symptoms are increasingly managed by medications and deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) or globus pallidus internus (GPI).
• The primary disease burden in PD is shifting towards non-dopaminergic manifestations, notably gait and posture disturbances.
• Current treatments show limited efficacy for these progressive, non-dopaminergic symptoms.

Purpose of the Study:

• To review the rationale for using pedunculopontine nucleus DBS (PPN-DBS) to treat parkinsonian gait disorder.
• To summarize the current status and findings of ongoing clinical trials investigating PPN-DBS.
• To assess the potential of PPN-DBS as a therapeutic option for gait impairment in Parkinson's disease.

Main Methods:

• Review of existing literature and preclinical animal models supporting PPN-DBS for gait disorders.
• Analysis of data from ongoing clinical trials evaluating PPN-DBS efficacy and safety.
• Assessment of the neurobiological underpinnings for targeting the PPN in PD.

Main Results:

• Evidence suggests the PPN plays a crucial role in motor control and gait, making it a potential therapeutic target.
• Early-phase clinical trials are exploring PPN-DBS, with preliminary data guiding further investigation.
• The efficacy of PPN-DBS for specific gait parameters in PD is under active evaluation.

Conclusions:

• Pedunculopontine nucleus DBS is a promising investigational therapy for parkinsonian gait disorder.
• Further research and clinical trials are necessary to establish the definitive role of PPN-DBS in managing PD.
• This approach may offer a new avenue for treating debilitating non-dopaminergic symptoms in Parkinson's disease.